Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.
-
July 27, 2026
Pfizer and Eisai Commence Co-promotion of “NURTEC®” for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
-
July 16, 2026
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
-
July 15, 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting
-
July 14, 2026
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.)
U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026
-
July 14, 2026
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer’s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer’s Association International Conference® (AAIC®) 2026
Measuring the plasma eMTBR-tau243 biomarker may serve as a practical, less invasive method of capturing Alzheimer's disease-specific pathological changes and may play an important role in etalanetug’s future clinical development
-
July 13, 2026
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners
-
July 2, 2026
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)
-
June 30, 2026
Eisai to Showcase Alzheimer’s Disease Portfolio with More Than 50 Presentations at the Alzheimer’s Association International Conference® 2026 (AAIC®)
-
June 30, 2026
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
-
June 26, 2026
Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approval
-
June 15, 2026
Eisai Announces Strategic Investment Supported by the UK Government’s LSIMF
Strategic investment in the Hatfield manufacturing site in the UK to help establish in-house capabilities for medicines requiring cold-chain management
-
June 4, 2026
Notification Regarding Issuance of Unsecured Straight Bonds
-
May 21, 2026
Eisai Deepens Body of Clinical Evidence for LENVIMA® (Lenvatinib) Across Established Indications at ASCO 2026
-
May 18, 2026
Eisai Selected for “SX Brands” 2026 for the First Time
-
May 15, 2026
Notification Regarding the Disposal of Treasury Stock in Connection with the Continuation of the Stock Compensation System (Officers’ Compensation BIP Trust)
-
May 15, 2026
Notification Regarding the Continuation of the Stock Compensation System (Officers’ Compensation BIP Trust)
-
May 8, 2026
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
-
April 29, 2026
Revenue of LEQEMBI® (Preliminary Basis)
-
April 21, 2026
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
-
March 27, 2026
Application Submitted for LENVIMA® (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG® (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
-
March 27, 2026
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline
Additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories
Taletrectinib is already approved in the U.S., China and Japan for advanced ROS1-positive non-small cell lung cancer
-
March 26, 2026
Notice of Nominees for Directors
-
March 23, 2026
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
-
March 19, 2026
Regarding Discontinuation of Administration of “Tazverik® Tablets 200mg” (tazemetostat hydrobromide)
-
March 17, 2026
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
-
March 12, 2026
Have Fun Exploring Sleep with Pokémon!
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokémon Sleep" Collaboration
-
March 11, 2026
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
-
March 2, 2026
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
This is the first positive Phase 3 trial of a multi-targeted tyrosine kinase inhibitor in combination with a HIF-2 alpha inhibitor, the first for patients with RCC whose disease progressed on or after treatment with anti-PD-1/L1 therapy, and the first to improve PFS compared to a modern tyrosine kinase inhibitor
Based on these data, the U.S. FDA accepts for review two supplemental New Drug Applications for WELIREG plus LENVIMA in certain previously treated patients with advanced RCC
-
February 16, 2026
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
-
February 9, 2026
Eisai Announces Appointment of Corporate Officers
-
February 9, 2026
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
-
February 6, 2026
Revenue of LEQEMBI® (Preliminary Basis)
-
February 5, 2026
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
-
January 26, 2026
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease
FDA action date set for May 24, 2026
-
January 21, 2026
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE TENTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 13, 2026
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Eisai will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of ROS1-positive non-small cell lung cancer in Europe, the Middle East, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India
Nuvation Bio will receive double-digit tiered royalties up to the high-teens as a percentage of taletrectinib sales in the licensed territories, in addition to up to €195 million (approx. USD $230 million) in upfront and milestone payments
Taletrectinib is already approved in the U.S., China, and Japan for advanced ROS1-positive non-small cell lung cancer
-
January 13, 2026
Changes of Corporate Officers
-
January 6, 2026
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer
an at-home injection from the initiation of treatment for this progressive, relentless disease
-
December 22, 2025
CHANGES OF CORPORATE OFFICERS
-
December 11, 2025
Eisai Rated “A”, the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
-
December 9, 2025
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
-
December 4, 2025
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at CTAD 2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from MCI to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage
New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States
-
December 3, 2025
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
-
December 2, 2025
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in phase Ib/II study
-
November 28, 2025
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease
-
November 26, 2025
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless disease
-
November 19, 2025
Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer’s Disease Conference
Latest findings from Eisai's robust Alzheimer's disease pipeline explore long-term treatment with lecanemab and estimated time savings over 10 years, safety and potential benefits of subcutaneous administration of lecanemab for initiation dosing
Oral and poster presentations also include data on the effects of lecanemab on soluble amyloid-β protofibrils and insights from real-world clinical practice studies, including the ALZ-NET Registry
-
November 14, 2025
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
-
November 7, 2025
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
October 30, 2025
Revenue of LEQEMBI® (Preliminary Basis)
-
October 29, 2025
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
-
October 28, 2025
Merck & Co., Inc., Rahway, NJ, USA and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
First treatment regimen to demonstrate a statistically significant improvement in PFS for patients whose disease progressed following anti-PD-1/L1 therapy, compared with cabozantinib in Phase 3 study
LITESPARK-011 marks the first positive Phase 3 study of a HIF-2 alpha inhibitor in combination with a multi-targeted VEGF tyrosine kinase inhibitor
-
October 27, 2025
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology
-
October 20, 2025
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
At five years, LENVIMA plus KEYTRUDA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the pivotal Phase 3 Study 309/KEYNOTE-775 trial
Five-year OS results in the pMMR subgroup were consistent with the all-comers study population, which demonstrated an OS rate of 19.9% for LENVIMA plus KEYTRUDA versus 7.7% for chemotherapy
-
October 14, 2025
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
-
October 7, 2025
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training,and an injection tracking tool and more
LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months
-
October 2, 2025
Eisai Highlights Breadth of Oncology Research at ESMO 2025
-
September 29, 2025
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
-
September 24, 2025
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
-
September 24, 2025
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
September 17, 2025
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
-
September 12, 2025
“New Answers to Dementia”
Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
-
September 8, 2025
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1
-
September 4, 2025
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
-
September 3, 2025
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease
-
August 30, 2025
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months
LEQEMBI IQLIK will be launched on October 6, 2025, in the U.S.
-
August 29, 2025
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to
Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
-
August 25, 2025
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
-
August 18, 2025
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China
-
July 31, 2025
Revenue of LEQEMBI® (Preliminary Basis)
-
July 31, 2025
Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease
56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four Years
-
July 31, 2025
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer’s disease, their care partners and healthcare professionals, with results showing a comparable efficacy and safety profile to the intravenous formulation
-
July 31, 2025
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
-
July 29, 2025
LENVIMA® (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
-
July 25, 2025
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
-
July 23, 2025
Launch of Beova® Tablets in Thailand for Overactive Bladder
-
July 22, 2025
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer’s Association International Conference 2025
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a subcutaneous form of lecanemab for continued treatment of AD
AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition
-
July 16, 2025
Eisai Awarded “The 9th Bioindustry Award”
for Drug Discovery Research for Anti- Amyloid β Monoclonal Antibody Lecanemab
-
July 14, 2025
“URECE®” (Dotinurad) Launched in China as a treatment for Gout
-
July 9, 2025
Update on the Cost-Effectiveness Evaluation of LEQEMBI® by the Central Social Insurance Medical Council of Japan’s Ministry of Health, Labour and Welfare
-
July 8, 2025
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
-
June 2, 2025
Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan
- Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product -
-
May 29, 2025
Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
May 27, 2025
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China
-
May 21, 2025
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
-
May 16, 2025
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro®
-
May 15, 2025
Notification Regarding Partial Amendment to the Articles of Incorporation
-
May 8, 2025
Notice Concerning Results of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
-
May 1, 2025
REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
-
April 29, 2025
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
-
April 16, 2025
Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology
Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD
-
April 14, 2025
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
-
April 1, 2025
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
-
March 28, 2025
“New Answers to Dementia”
Eisai Launches Corporate Awareness Campaign
-
March 28, 2025
EISAI TO DIVEST RIGHTS FOR PARIET® IN CHINA TO PEAK PHARMA
-
March 27, 2025
Eisai to Divest Rights for Warfarin in Japan to Sawai
-
March 27, 2025
Eisai to Present the Latest Research Results, Including Long-Term and
Real-Word Data on Lecanemab and Biomarkers for Alzheimer’s Disease at the AD/PD™ 2025 Annual Meeting
-
March 25, 2025
World’s First Early Alzheimer’s Disease Treatment Developed in Japan LEQEMBI® Receives Prime Minister’s Award at the 12th Technology Management and Innovation Awards
-
March 24, 2025
EISAI SELECTED AS A NADESHIKO BRAND 2025 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE
-
March 21, 2025
Proton Pump Inhibitor “Pariet® S” Approved in Japan as RX-to-OTC Switch
Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product
-
March 14, 2025
Notice Concerning Commencement of Tender Offer by Eisai Co., Ltd. for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
-
March 10, 2025
EISAI RECOGNIZED AS “2025 KENKO INVESTMENT FOR HEALTH” FOR THE FIRST TIME AND CERTIFIED AS “OUTSTANDING ORGANIZATION OF KENKO INVESTMENT FOR HEALTH PROGRAM (WHITE 500)” FOR THE SIXTH TIME
-
March 7, 2025
Eisai Announces Appointments of Corporate Officers
-
March 7, 2025
Notice of Nominees for Directors
-
March 7, 2025
Notification Regarding Changes in Representative Corporate Officers
-
March 4, 2025
UPDATE ON THE CO-PROMOTION OF THE ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG IN JAPAN
-
March 3, 2025
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
-
March 3, 2025
“Fatigue Recovery While You Sleep!” Eisai to Launch Designated Quasi-Drug Drink “Chocola BB® Nightwell”
Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine
-
February 28, 2025
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
-
February 28, 2025
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
-
February 20, 2025
EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2024” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY” FOR SECOND CONSECUTIVE YEAR,
AS A COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
-
February 14, 2025
DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION FOR EARLY SCREENING OF ALZHEIMER’S DISEASE
MACHINE LEARNING MODEL USING DATA THAT CAN BE COLLECTED IN DAILY MEDICAL EXAMINATIONS BY PRIMARY CARE PHYSICIANS
-
February 6, 2025
Eisai Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security
-
February 3, 2025
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
-
January 31, 2025
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
-
January 27, 2025
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of
Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy
-
January 24, 2025
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-015 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
-
January 23, 2025
Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”
-
January 22, 2025
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE NINTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 14, 2025
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience
of a subcutaneous injection with at-home administration option
-
January 7, 2025
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer’s Disease
